|
0
|
|
Screening and Vaccination Rates for Tetanus, Hepatitis A, and Hepatitis B Among Individuals With Substance Use Disorders Hospitalized in an Integrated US Health System.
(academic.oup.com)
|
Ku JH
…
Varley CD
Clinical Infectious Diseases
2026-04-30
|
#vaccination
#screening
#substance use disorder
#preventive care
|
|
0
|
|
Approaches to Comparing Influenza Vaccine Effectiveness to Guide Potential Preferential Product Recommendations.
(academic.oup.com)
|
Belongia EA
…
Petrie JG
Clinical Infectious Diseases
2026-04-30
|
#vaccination
#influenza
#immunogenicity
#observational
#efficacy
|
|
0
|
|
Analysis of Antibody Markers as Immune Correlates of Risk of Severe COVID-19 in the PREVENT-19 Efficacy Trial of the NVX-CoV2373 Recombinant Protein Vaccine.
(academic.oup.com)
|
Fong Y
…
Gilbert PB
Clinical Infectious Diseases
2026-04-30
|
#covid-19
#vaccination
#immunity
#antibody
#neutralization
|
|
0
|
|
Bivalent mRNA booster encoding virus-like particles elicits potent polyclass receptor-binding domain antibodies in pre-vaccinated mice.
(elifesciences.org)
|
Fan C
…
Hoffmann MAG
eLife
2026-04-30
|
#covid-19
#vaccination
#antibody
#rna
#immunology
|
|
0
|
|
Immunogenicity and Safety of 2 Versus 3 Doses of 9-Valent Vaccine Against Human Papillomavirus in Women With Human Immunodeficiency Virus: The Papillon Randomized Trial.
(academic.oup.com)
|
Konopnicki D
…
De Wit S
Clinical Infectious Diseases
2026-04-30
|
#vaccination
#immunogenicity
#hiv
#immunocompromised
#seroconversion
|
|
0
|
|
Safety, Tolerability, and Immunogenicity of Revaccination With mRNA-1345, an mRNA Vaccine Against Respiratory Syncytial Virus, Administered 12 Months Following a Primary Dose in Adults Aged >/=50 Years.
(academic.oup.com)
|
Goswami J
…
Das R
Clinical Infectious Diseases
2026-04-30
|
#vaccination
#rna
#immunogenicity
#safety
#rsv
|
|
0
|
|
Is It Time to Reassess the Target Age of Human Papillomavirus Vaccination Globally?
(academic.oup.com)
|
Brassington E
…
Hill A
Clinical Infectious Diseases
2026-04-30
|
#vaccination
#cancer
#prevention
#immunogenicity
#hpv
|
|
0
|
|
Real-world effectiveness of 20-valent pneumococcal conjugate vaccine against all-cause outcomes among Medicare beneficiaries aged 65 years and older in the USA: a retrospective cohort study.
(linkinghub.elsevier.com)
|
Miles AC
…
Cane A
Lancet Infectious Diseases
2026-04-30
|
#infection
#vaccination
#epidemiology
#elderly
#pneumococcal
|
|
0
|
|
Atrial Fibrillation After Respiratory Syncytial Virus Vaccination Among Older Adults.
(academic.oup.com)
|
Birabaharan M
…
Mehta SR
Clinical Infectious Diseases
2026-04-30
|
#vaccination
#safety
#arrhythmia
|
|
0
|
|
LC16m8 for Pre-exposure Prophylaxis Against Mpox in a High-Risk Population: An Open-Label Randomized Trial.
(academic.oup.com)
|
Okumura N
…
Ujiie M
Clinical Infectious Diseases
2026-04-30
|
#vaccination
#prophylaxis
#immunogenicity
#hiv
#mpox
|
|
0
|
|
Impact of Respiratory Syncytial Virus Immunization on the Rate of Pediatric Acute Otitis Media: A Time-series Analysis.
(academic.oup.com)
|
Fafi I
…
Cohen R
Clinical Infectious Diseases
2026-04-30
|
#infection
#vaccination
#pediatric
#otitis
|
|
0
|
|
Effective Antivirals in Pandemic Preparedness: Past Mistakes, Future Needs.
(academic.oup.com)
|
Panagiotopoulos AP
…
Ioannidis JPA
Clinical Infectious Diseases
2026-04-30
|
#vaccination
#clinical trial
#antiviral
#pandemic
#drug development
|
|
0
|
|
High-resolution in situ structures of hantavirus glycoprotein tetramers.
(linkinghub.elsevier.com)
|
Guo L
…
McLellan JS
Cell
2026-04-30
|
#vaccination
#cryo-em
#glycoprotein
#hantavirus
#viral assembly
|
|
0
|
|
Disease Trends and Mortality From Invasive Pneumococcal Disease: A Long-Term Population-Based Study.
(academic.oup.com)
|
Bragason HT
…
Gottfreethsson M
Clinical Infectious Diseases
2026-04-30
|
#infection
#vaccination
#epidemiology
#surveillance
#mortality
|